Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | RIPK1 | Q13546 | 5/20 | 0.52 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | WNT3A | P56704 | 1/20 | 0.38 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14691598 | 0.92 | RIPK1 (0.53) | NPSR1RIPK1NOTUMALDH1A1PDE4B | |
| SCHEMBL15930179 | 0.90 | RIPK1 (0.48) | NPSR1RIPK1NOTUMALDH1A1PDE4B | |
| SCHEMBL14691494 | 0.87 | PDE4B (0.60) | NPSR1RIPK1NOTUMALDH1A1PDE4B | |
| SCHEMBL20209694 | 0.86 | RIPK1 (0.45) | NPSR1RIPK1NOTUMALDH1A1PDE4B | |
| SCHEMBL17365310 | 0.86 | RIPK1 (0.46) | NPSR1RIPK1NOTUMALDH1A1PDE4B | |
| SCHEMBL15933267 | 0.80 | MAPT (0.55) | NPSR1RIPK1NOTUMALDH1A1LMNA | |
| SCHEMBL17563304 | 0.78 | NOTUM (0.51) | NPSR1RIPK1NOTUMPDE4BMDM2 | |
| SCHEMBL18945281 | 0.77 | RIPK1 (0.43) | NPSR1RIPK1NOTUMALDH1A1PDE4B | |
| SCHEMBL15933238 | 0.76 | RIPK1 (0.46) | RIPK1NOTUMALDH1A1MDM2LMNA | |
| SCHEMBL17364461 | 0.75 | NOTUM (0.45) | NPSR1RIPK1NOTUMPDE4BMDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170158712-A1 | NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-06-08 | — | — | US | disclosed |
| US-9611274-B2 | Macrocycles as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-04-04 | — | — | US | disclosed |
| US-20160068544-A1 | NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-03-10 | — | — | US | disclosed |
| US-9221818-B2 | Macrocycles as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-12-29 | — | — | US | disclosed |
| US-20140221338-A1 | NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160068544-A1 | NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F12 | NPSR1 3472/4885RIPK1 773/4885NOTUM 2506/4885 |
| US-20140221338-A1 | NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F12 | NPSR1 3472/4885RIPK1 773/4885NOTUM 2506/4885 |
| US-20170158712-A1 | NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F12 | NPSR1 3472/4885RIPK1 773/4885NOTUM 2506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.